What is Chembio Diagnostics, Inc. (CEMI)?

Chembio Diagnostics, Inc. (CEMI) is a stock in the Healthcare sector, Medical - Diagnostics & Research industry. View full analysis on Stocks360.

What is the current price of CEMI?

The current price of CEMI is $0.46. Prices are updated in real time on Stocks360.

What is CEMI's price-to-earnings (PE) ratio?

CEMI's trailing twelve-month PE ratio is -0.47, based on current price and earnings per share data available on Stocks360.

What is CEMI's market capitalization?

CEMI's market capitalization is $16,710,285.00, placing it in the small-cap tier.

Chembio Diagnostics, Inc. (CEMI)

Stock analysis · NASDAQ · Healthcare · Medical - Diagnostics & Research

$0.46

Market Cap

$16.71M

PE (TTM)

-0.47

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.86

Day Range

$0.46 – $0.46

52-wk Range

$0.19 – $1.24

Avg Volume

N/A

Volume

351.64K

Chembio Diagnostics, Inc. (CEMI) is a publicly traded company in the Healthcare sector. Latest price: $0.46. Market cap $16.71M. Trailing PE -0.47. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

May 5, 2022

EPS $-0.29 vs est. $-0.21

Missed by $0.08

Proprietary Signals

Signal snapshot temporarily unavailable.

About Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc., along with its subsidiaries, specializes in creating, producing, and bringing to market point-of-care (POC) diagnostic tests used for identifying and diagnosing various diseases. Their current product offerings include tests for critical conditions like COVID-19, HIV/Syphilis, and the Zika virus. Beyond these, the company is dedicated to advancing diagnostics for a wide array of other infectious diseases, such as malaria, dengue, chikungunya, Chagas disease, Ebola, leishmaniasis, Lassa fever, Marburg virus, leptospirosis, rickettsia, and Burkholderia infections. These diagnostic tools are sold under well-known brand names including STAT-PAK, SURE CHECK, STAT VIEW, and DPP. Chembio distributes its products directly and through various partners to a diverse global customer base. This clientele includes medical laboratories, hospitals, government and public health agencies, non-governmental organizations (NGOs), medical professionals, and retail outlets across the United States and worldwide. The company engages in strategic partnerships with prominent organizations such as the Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswald…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.47×
P/S (TTM)	0.35×
P/B	0.62×
P/FCF (TTM)	-1.18×
EV / EBITDA	-1.00×
EV / Sales	0.49×
Earnings Yield	-210.66%
Free Cash Flow Yield	-84.65%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$23.61M
Revenue (TTM)	$48.34M
Net Income (TTM)	-$35.20M
Free Cash Flow (TTM)	-$13.76M
Net Debt	$6.90M
Working Capital	$9.15M
Gross Margin	20.19%
Operating Margin	-42.21%
Net Margin	-48.18%
Return on Equity	-89.47%
Return on Invested Capital	-47.58%